Summary
This research investigates the use of raloxifene, an FDA-approved drug acting on CB2 receptors, to mitigate visual impairments following mild TBI and/or ocular trauma, which are prevalent in military populations. The findings could inform clinical protocols for preserving vision in trauma patients, though direct lighting design implications are limited.
Categories
Eye Health & Vision: The paper addresses visual deficits resulting from traumatic brain injury and ocular trauma, with focus on retinal and visual system damage.
Author(s)
A Reiner
Publication Year
2018
Related Publications
Eye Health & Vision
- Diminished pupillary light reflex at high irradiances in melanopsin-knockout mice
- Genetic reactivation of cone photoreceptors restores visual responses in retinitis pigmentosa
- Melanopsin and rod–cone photoreceptors play different roles in mediating pupillary light responses during exposure to continuous light in humans
- Characteristic patterns of dendritic remodeling in early-stage glaucoma: evidence from genetically identified retinal ganglion cell types
- Intrinsically photosensitive melanopsin retinal ganglion cell contributions to the pupillary light reflex and circadian rhythm